Abstract
In 2012, Nature Reviews Immunology organized a conference that brought together scientists and clinicians from both academia and industry to discuss one of the most pressing questions in medicine — how do we turn off rampant, undesirable inflammation? There is a growing appreciation that, similarly to the initiation of inflammation, the resolution of inflammation is an intricate and active process. Can we therefore harness the mediators involved in resolution responses to treat patients with chronic inflammatory or autoimmune diseases? Here, we ask five of the speakers from the conference to share their thoughts on this emerging field.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
£139.00 per year
only £11.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
10 December 2012
In the abstract of the original version of this article, the date of the conference was given as 2011 instead of 2012. This has now been corrected online. Nature Reviews Immunology apologizes for this error.
References
Gilroy, D. W., Lawrence, T., Perretti, M. & Rossi, A. G. Inflammatory resolution: new opportunities for drug discovery. Nature Rev. Drug Discov. 3, 401–416 (2004).
Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025–1037 (2002).
Gilroy, D. W. & Perretti, M. Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr. Opin. Pharmacol. 5, 405–411 (2005).
Serhan, C. N. & Savill, J. Resolution of inflammation: the beginning programs the end. Nature Immunol. 6, 1191–1197 (2005).
Serhan, C. N. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem. Cell Biol. 122, 305–321 (2004).
Frazier, W. J. et al. Increased inflammation, impaired bacterial clearance, and metabolic disruption after Gram-negative sepsis in Mkp-1-deficient mice. J. Immunol. 183, 7411–7419 (2009).
Olofsson, P. S., Rosas-Ballina, M., Levine, Y. A. & Tracey, K. J. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol. Rev. 248, 188–204 (2012).
Metchnikoff, E. Immunity in Infective Diseases (Cambridge Univ. Press, 1905).
Tauber, A. I. & Chernyak, L. Metchnikoff and the Origins of Immunology: From Metaphor to Theory (Oxford Univ. Press, 1991).
Savill, J. S., Henson, P. M. & Haslett, C. Phagocytosis of aged human neutrophils by macrophages is mediated by a novel “charge-sensitive” recognition mechanism. J. Clin. Invest. 84, 1518–1527 (1989).
Serhan, C. N. et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2–nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197–1204 (2000).
Serhan, C. N. et al. Macrophage pro-resolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 26, 1755–1765 (2012).
Serhan, C. N. et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325–332 (2007).
Mitchell, S. et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13, 2497–2507 (2002).
Lawrence, T., Gilroy, D. W., Colville-Nash, P. R. & Willoughby, D. A. Possible new role for NF-κB in the resolution of inflammation. Nature Med. 7, 1291–1297 (2001).
Hyman, M. C. et al. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J. Clin. Invest. 119, 1136–1149 (2009).
Majno, G. & Joris, I. Cells, Tissues and Disease: Principles of General Pathology (Blackwell Science, 1996).
Yamada, T. et al. Eosinophils promote resolution of acute periotonitis by producing proresolving mediators in mice. FASEB J. 25, 561–568 (2011).
Haworth, O., Cernadas, M., Yang, R., Serhan, C. N. & Levy, B. D. Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammation. Nature Immunol. 9, 873–879 (2008).
Ariel, A. et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280, 43079–43086 (2005).
Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524–528 (2012).
Uderhardt, S. et al. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 36, 834–846 (2012).
Rajakariar, R. et al. Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood 111, 4184–4192 (2008).
Didierlaurent, A. et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J. Exp. Med. 205, 323–329 (2008).
Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest. 115, 56–65 (2005).
Stables, M. J. et al. Transcriptomic analyses of murine resolution-phase macrophages. Blood 118, e192–e208 (2012).
Fang, Y., Sharp, G. C., Yagita, H. & Braley-Mullen, H. A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis. J. Pathol. 216, 505–513 (2008).
Buckley, C. D. et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 22, 199–204 (2001).
Parsonage, G. et al. A stromal address code defined by fibroblasts. Trends Immunol. 26, 150–156 (2005).
Sherlock, J. P. et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells. Nature Med. 18, 1069–1076 (2012).
van Maanen, M. A., Stoof, S. P., Larosa, G. J., Vervoordeldonk, M. J. & Tak, P. P. Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor α7 subunit gene knockout mice. Ann. Rheum. Dis. 69, 1717–1723 (2010).
Cutolo, M., Foppiani, L. & Minuto, F. Hypothalamic–pituitary–adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J. Endocrinol. Invest. 25, 19–23 (2002).
McGettrick, H. M., Butler, L. M., Buckley, C. D., Rainger, G. E. & Nash, G. B. Tissue stroma as a regulator of leukocyte recruitment in inflammation. J. Leukoc. Biol. 91, 385–400 (2012).
Tak, P. P., Zvaifler, N. J., Green, D. R. & Firestein, G. S. Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol. Today 21, 78–82 (2000).
Murdoch, J. R. & Lloyd, C. M. Resolution of allergic airway inflammation and airway hyperreactivity is mediated by IL-17-producing γδ T cells. Am. J. Respir. Crit. Care Med. 182, 464–476 (2010).
Torchinsky, M. B., Garaude, J., Martin, A. P. & Blander, J. M. Innate immune recognition of infected apoptotic cells directs TH17 cell differentiation. Nature 458, 78–82 (2009).
Segal, A. W., Geisow, M., Garcia, R., Harper, A. & Miller, R. The respiratory burst of phagocytic cells is associated with a rise in vacuolar pH. Nature 290, 406–409 (1981).
Pollock, J. D. et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nature Genet. 9, 202–209 (1995).
Calabro, S. et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29, 1812–1823 (2011).
Dadabhoy, D. & Clauw, D. J. Therapy insight: fibromyalgia — a different type of pain needing a different type of treatment. Nature Clin. Pract. Rheumatol. 2, 364–372 (2006).
Brittijn, S. A. et al. Zebrafish development and regeneration: new tools for biomedical research. Int. J. Dev. Biol. 53, 835–850 (2009).
Chapple, I. L., Socransky, S. S., Dibart, S., Glenwright, H. D. & Matthews, J. B. Chemiluminescent assay of alkaline phosphatase in human gingival crevicular fluid: investigations with an experimental gingivitis model and studies on the source of the enzyme within crevicular fluid. J. Clin. Periodontol. 23, 587–594 (1996).
Chan, M. M.-Y. & Moore, A. R. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 184, 6418–6426 (2010).
Gilroy, D. W. et al. Inducible cyclooxygenase may have anti-inflammatory properties. Nature Med. 5, 698–701 (1999).
Bannenberg, G. L. et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345–4355 (2005).
Navarro-Xavier, R. A. et al. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184, 1516–1525 (2010).
Pillai, P. S. et al. Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients. Inflammation 35, 98–113 (2012).
Mulero, V., Sepulcre, M. P., Rainger, G. E. & Buckley, C. D. Editorial: neutrophils live on a two-way street. J. Leukoc. Biol. 89, 645–647 (2011).
Padmakumar, V. C. et al. Spontaneous skin erosions and reduced skin and corneal wound healing characterize CLIC4NULL mice. Am. J. Pathol. 181, 74–84 (2012).
Perretti, M. et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nature Med. 8, 1296–1302 (2002).
Rossi, A. G. et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nature Med. 12, 1056–1064 (2006).
Burstein, S. H., McQuain, C. A., Ross, A. H., Salmonsen, R. A. & Zurier, R. E. Resolution of inflammation by N-arachidonoylglycine. J. Cell. Biochem. 112, 3227–3233 (2011).
Yanes, O. et al. Metabolic oxidation regulates embryonic stem cell differentiation. Nature Chem. Biol. 6, 411–417 (2010).
Gerlag, D. M. et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann. Rheum. Dis. 71, 638–641 (2012).
Serezani, C. H. et al. Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase. Am. J. Respir. Cell Mol. Biol. 37, 562–570 (2007).
Aronoff, D. M., Canetti, C. & Peters-Golden, M. Prostaglandin E2 inhibits alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated increase in intracellular cyclic AMP. J. Immunol. 173, 559–565 (2004).
Stables, M. J. et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood 116, 2950–2959 (2010).
Aronoff, D. M. et al. E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection. J. Immunol. 183, 2642–2649 (2009).
Spite, M. et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287–1291 (2009).
Seki, H. et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184, 836–843 (2010).
Wu, S. H., Chen, X. Q., Liu, B., Wu, H. J. & Dong, L. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br. J. Dermatol. 27 Jul 2012 (doi:10.1111/j.1365-2133.2012.11177.x).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Charles N. Serhan is an inventor on patents (for lipoxins and resolvins) assigned to Brigham and Women's Hospital and licensed to Resolvyx Pharmaceuticals. He is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. His interests were reviewed and are managed by the Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies.
Paul P. Tak is an employee of GlaxoSmithKline.
The other authors declare no competing financial interests.
Related links
FURTHER INFORMATION
Glossary
- Cholinergic anti-inflammatory pathway
-
A mechanism for neural inhibition of local and systemic inflammation that is controlled by vagus nerve stimulation.
- Efferocytosis
-
The process by which dead or dying cells are removed through engulfment by phagocytes.
- Eicosanoids
-
(Also known as icosanoids). A general term used to denote bioactive lipid mediators that contain 20 carbon atoms and are synthesized from arachidonic acid (a fatty acid present in membrane phospholipids) by the initial activities of either cyclooxygenases or lipoxygenases. Examples include prostaglandins, leukotrienes and lipoxins. Eicosanoids signal through G protein-coupled receptors and have important roles in inflammation, but also in many other biological processes, including reproduction and haemostasis.
- Enthesis
-
The region at the junction between tendon and bone. This is a key site of pathology in spondyloarthritic diseases, such as ankylosing spondylitis.
- Exudates
-
Biological fluids that filter from the circulatory system into lesions or areas of inflammation. Exudate is characterized by a high content of plasma proteins, cells and cellular debris. Pus is an example of an exudate found in infected wounds and it contains bacteria and high concentrations of white blood cells.
- Immunoresolvents
-
A term that denotes agents that stimulate the resolution of inflammation. Examples include lipoxins, resolvins and protectins.
- Innate lymphoid cells
-
Lymphoid cells that do not express unique antigen receptors derived from gene rearrangement or cell-surface markers that are characteristic of other immune cell lineages. However, in response to innate tissue-derived signals, they secrete cytokines that are associated with T helper cell subsets. They can promote protective immunity during infection, but may also have pathological roles in certain diseases.
- Leukotrienes
-
A class of eicosanoids derived from arachidonic acid by the action of arachidonate 5-lipoxygenase and downstream enzymes. They have a conjugated triene double-bond structure and various pro-inflammatory activities, including leukocyte activation (in the case of leukotriene B4) and bronchoconstriction (in the case of leukotriene C4 and leukotriene D4).
- Lipoxins
-
A class of eicosanoids that are produced by lipoxygenase-mediated metabolism of arachidonic acid. They are trihydroxytetraene-containing structures with potent biological activities in the resolution of inflammation.
- NADPH oxidase
-
NADPH oxidases are plasma membrane- and phagosomal membrane-bound enzyme complexes that transfer electrons from NADPH to molecular oxygen, promoting the generation of the reactive oxygen species superoxide.
- Positional memory
-
The basis by which cells know their spatial relationship to each other (in terms of top or bottom, left or right and inside or outside) is defined during embryological development. This relative 'positioning' of one cell to another is generally 'remembered' throughout life. However, during tissue pathology (for example, in cancer and during inflammation) positional memory can be lost.
- Prostaglandins
-
Cyclopentane-ring-containing lipids derived from the metabolism of arachidonic acid by the action of cyclooxygenases and downstream synthase enzymes. They have a diverse range of biological activities and a well-recognized role in inflammation and pain.
- Protectins
-
A family of docosahexaenoic acid-derived mediators characterized by the presence of a conjugated triene double-bond structure and 22 carbons with 6 double bonds.
- Resolvins
-
Lipid mediators that are induced in the resolution phase following acute inflammation. They are biosynthesized from the essential omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid.
- Type 1 hypersensitivity responses
-
Immediate allergic reactions to allergens in previously sensitized individuals. These responses are mediated by pre-existing allergen-specific IgE antibodies, which promote the activation and degranulation of tissue mast cells and basophils in the blood.
Rights and permissions
About this article
Cite this article
Buckley, C., Gilroy, D., Serhan, C. et al. The resolution of inflammation. Nat Rev Immunol 13, 59–66 (2013). https://doi.org/10.1038/nri3362
Published:
Issue Date:
DOI: https://doi.org/10.1038/nri3362